Clinical Trial Update: Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating NXN-462 for postherpetic neuralgia reports on its efficacy, tolerability, and safety; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• NXN-462

Snippet

Sponsor: NeurAxon Inc. | Conditions: Post Herpetic Neuralgia | Phase 2 | Status: COMPLETED